The impacts of COVID-19 are severe and too numerous to address in a single literary examination. While we acknowledge the massive public health and economic impact of the pandemic, this 3-part blog series will focus on a specific ramification of COVID-19’s decimation of the U.S. job market: patient health insurance and how patients are paying for their prescriptions.
As we all know, non-Government (aka Commercial) payers enroll most of their patients via employer-sponsored plans. Employers can choose to subsidize the employee premiums as a benefit of employment, and patients do not need to worry about being excluded from insurance rolls due to pre-existing conditions. While this system is robust and works for millions of Americans, it is ill-equipped to deal with the high levels of mass unemployment that we are currently experiencing.
In the world of pharmaceuticals, the complicated web of stakeholders is enabled by the basic assumption that most patients have a health insurer negotiating costs on their behalf. Any disruption to this model has a substantial impact on patient cost sharing, payer expenses, and manufacturer sales and margin – the latter which we focus on in this blog series.
Coverage Options
A patient who has recently become unemployed has five options:
Each of these options has a different impact on a manufacturer’s commercial strategy and finances, and it is vital to track these coverage options to minimize disruption of sales and margins.
Because the ratio of patients selecting these coverage options differ by geography and therapeutic area, there is no one-size-fits-all approach when it comes to strategic responses.
This resource is Part 1 of a blog series dedicated to Payer Coverage changes in the time of COVID-19. Our next post will address the two commercial questions manufacturers must answer amid payer coverage changes.
For more guidance on how to track payer coverage, contact Brian Fallica.